{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:10:33Z","timestamp":1794719433249,"version":"4.9.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain resulting from infection of oligodendrocytes by JC virus (JCV) typically occurring in association with defects of cell-mediated immunity. The clinical presentation of PML depends on its area of effect in the central nervous system and can include a broad spectrum of deficits such as focal weakness, speech difficulties, visual changes, cognitive disruptions, or ataxia. While the disease was first described in patients with B cell malignancies (Hodgkins\u2019s lymphoma and chronic lymphocytic leukemia), a large array of immunosuppressive conditions, most notably human immunodeficiency virus, may predispose to the disorder. From 2005 on, PML was observed in patients with multiple sclerosis (MS) and Crohn\u2019s disease being treated with natalizumab, a monoclonal antibody inhibiting \u03b14\u03b21 and \u03b14\u03b27 integrins. Risk factors for PML development were identified, and an effective risk mitigation strategy chiefly predicated on the JCV antibody index was established (an antibody index less than 0.4 is considered negative, 0.4 to 0.9 low risk, 0.9 to 1.5 medium risk, and greater than 1.5 high risk). Here we review risk stratification, diagnosis, and treatment of PML in patients receiving natalizumab.<\/jats:p>","DOI":"10.3389\/fneur.2025.1575653","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:35Z","timestamp":1750392635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Natalizumab-associated progressive multifocal leukoencephalopathy"],"prefix":"10.3389","volume":"16","author":[{"given":"Trevor","family":"Glenn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb R. S.","family":"McEntire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s13365-023-01164-w","article-title":"Revisiting JC virus and progressive multifocal leukoencephalopathy","volume":"29","author":"Rocchi","year":"2023","journal-title":"J Neurovirol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/brain\/awab419","article-title":"The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective","volume":"145","author":"Baldassari","year":"2021","journal-title":"Brain"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/839719","article-title":"New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy","volume":"2013","author":"Bellizzi","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1212\/NXI.0000000000000618","article-title":"Progressive multifocal leukoencephalopathy","volume":"6","author":"Anand","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with Natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.msard.2019.05.026","article-title":"The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study","volume":"33","author":"Curti","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1007\/s10072-021-05127-z","article-title":"Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years","volume":"42","author":"Guerra","year":"2021","journal-title":"Neurol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s00415-016-8343-5","article-title":"Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-na\u00efve patients with multiple sclerosis","volume":"264","author":"Prosperini","year":"2017","journal-title":"J Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e00537","DOI":"10.1016\/j.neurot.2025.e00537","article-title":"Comparative effectiveness, safety and persistence of ocrelizumab versus natalizumab in multiple sclerosis: a real-world, multi-center, propensity score-matched study","volume":"22","author":"Barbuti","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/acn3.52118","article-title":"A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis","volume":"11","author":"Iaffaldano","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ana.21630","article-title":"Opportunistic infections and other risks with newer multiple sclerosis therapies","volume":"65","author":"Berger","year":"2009","journal-title":"Ann Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"iii64-65","DOI":"10.1136\/ard.2008.097972","article-title":"Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies","volume":"67","author":"Calabrese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamaneurol.2014.63","article-title":"JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab","volume":"71","author":"Frohman","year":"2014","journal-title":"JAMA Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.msard.2014.01.005","article-title":"Progressive multifocal leukoencephalopathy and JC virus-related disease in modern neurology practice","volume":"3","author":"Carruthers","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflam"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti\u2013JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jnnp-2015-311100","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1101\/2025.02.05.25320428","article-title":"Real-world experience with switching from originator to biosimilar natalizumab","author":"H\u00f8gest\u00f8l","year":"2025"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X372688250226110925","article-title":"Comparing STRATIFY JCV\u2122 DxSelect\u2122 and IMMUNOWELL\u2122 JCV IgG tests in RRMS to assess PML risk","author":"Zangh\u00ec","year":"2025","journal-title":"Curr Neuropharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1177\/1352458519854162","article-title":"Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate","volume":"26","author":"Scarpazza","year":"2020","journal-title":"Mult Scler"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/jnnp-2016-313772","article-title":"MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance","volume":"87","author":"Wijburg","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1212\/WNL.0000000000002586","article-title":"Punctate pattern","volume":"86","author":"Hodel","year":"2016","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e2232","DOI":"10.1212\/WNL.0000000000007451","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in Germany","volume":"92","author":"Blankenbach","year":"2019","journal-title":"Neurology"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","article-title":"Outcome and survival of asymptomatic PML in natalizumab-treated MS patients","volume":"1","author":"Dong-Si","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1756285608101861","article-title":"Natalizumab in the treatment of multiple sclerosis","volume":"2","author":"Yaldizli","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/WNL.0000000000003740","article-title":"No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML","volume":"88","author":"Landi","year":"2017","journal-title":"Neurology"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ana.25070","article-title":"To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy","volume":"82","author":"Scarpazza","year":"2017","journal-title":"Ann Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1212\/WNL.0000000000207622","article-title":"Progressive multifocal leukoencephalopathy","volume":"101","author":"Schweitzer","year":"2023","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","article-title":"Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 team","volume":"338","author":"Hall","year":"1998","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/13550289809114545","article-title":"The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line","volume":"4","author":"Hou","year":"1998","journal-title":"J Neurovirol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1006\/viro.1993.1517","article-title":"Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin","volume":"196","author":"Kerr","year":"1993","journal-title":"Virology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/13550280390201740","article-title":"Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy","volume":"9","author":"Royal","year":"2003","journal-title":"J Neurovirol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1103492","article-title":"The human polyomavirus, JCV, uses serotonin receptors to infect cells","volume":"306","author":"Elphick","year":"2004","journal-title":"Science"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4255","article-title":"Favorable response to mirtazapine in John Cunningham virus-related gray matter lesion in a patient with human immunodeficiency virus","volume":"11","author":"Alwehaibi","year":"2019","journal-title":"Cureus"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/archneurol.2008.557","article-title":"Mirtazapine use in human immunodeficiency virus\u2013infected patients with progressive multifocal leukoencephalopathy","volume":"66","author":"Cettomai","year":"2009","journal-title":"Arch Neurol"},{"key":"ref50","first-page":"33","article-title":"The benefit of mirtazapine in the treatment of progressive multifocal leukoencephalopathy in a young HIV-positive patient","volume":"15","author":"Mullins","year":"2018","journal-title":"Innov Clin Neurosci"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.jocn.2013.12.031","article-title":"Mefloquine improved progressive multifocal leukoencephalopathy in a patient with immunoglobulin a nephropathy","volume":"21","author":"Shin","year":"2014","journal-title":"J Clin Neurosci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"Clifford","year":"2013","journal-title":"J Neurovirol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.clpt.2006.07.003","article-title":"MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine","volume":"80","author":"Aarnoudse","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/acn3.776","article-title":"Treatment of natalizumab-associated PML with filgrastim","volume":"6","author":"Stefoski","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1212\/NXI.0000000000000627","article-title":"Ineffective treatment of PML with pembrolizumab","volume":"6","author":"Pawlitzki","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2024.3324","article-title":"Directly isolated allogeneic virus\u2013specific T cells in progressive multifocal leukoencephalopathy","volume":"81","author":"M\u00f6hn","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/ana.26307","article-title":"Outcome of progressive multifocal leukoencephalopathy treated by interleukin-7","volume":"91","author":"Lajaunie","year":"2022","journal-title":"Ann Neurol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e213","DOI":"10.1212\/NXI.0000000000000213","article-title":"Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia","volume":"3","author":"Miskin","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00277-002-0481-4","article-title":"Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin\u2019s lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy","volume":"81","author":"Buckanovich","year":"2002","journal-title":"Ann Hematol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1212\/01.wnl.0000183064.10227.b5","article-title":"Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2","volume":"65","author":"Kunschner","year":"2005","journal-title":"Neurology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.bmt.1701010","article-title":"Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2","volume":"20","author":"Przepiorka","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"ref64","article-title":"PML tools and StratifyJCV","year":"2025"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e1021","DOI":"10.1212\/NXI.0000000000001021","article-title":"Single-dose pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"8","author":"Beudel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1575653\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:10:35Z","timestamp":1750392635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1575653\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":65,"alternative-id":["10.3389\/fneur.2025.1575653"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1575653","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1575653"}}